Clinical Trials Logo

Clinical Trial Summary

The rise of oral therapies in the management of cancers has considerably changed the patient care path. If the oral route is preferred by patients because it offers a better quality of life, it is not without impact for patients and the health professionals involved in their management in their care. Indeed, the use of the oral route shifts part of the responsibility for monitoring treatment towards the patient, thereby leading to compliance problems, drug interactions and the management of adverse effects.These risks can cause complications or compromise the effectiveness of treatment, and generate additional costs for the investigator's health system. The study proposes to involve Healthcare Facilities Pharmacist and the Dispensary Pharmacist with all other health professionals.First, the hospital pharmacist will operate before the initiation of an oral route to perform a clinical pharmaceutical analysis of drug prescriptions. Then after the primary prescription and finally during a follow-up consultation 3 months after the initiation of treatment. The hypothesis of the study is that the coordinated intervention of the hospital pharmacist and of the dispensary pharmacist would improve the tolerance of oral treatments by reducing the number of serious adverse effects found, as well as improve the, quality of life, patient and professional satisfaction


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04327583
Study type Interventional
Source Institut Cancerologie de l'Ouest
Contact Fanny D'ACREMONT-JUTIER
Phone 02 40 84 64 47
Email fanny.jutier@chu-nantes.fr
Status Recruiting
Phase N/A
Start date April 7, 2021
Completion date October 2024

See also
  Status Clinical Trial Phase
Completed NCT03096821 - Extended Analysis for Leukemia/Lymphoma Treatment
Recruiting NCT05956457 - PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma N/A
Active, not recruiting NCT03560882 - A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies Phase 1
Recruiting NCT03821519 - Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant Phase 1/Phase 2
Recruiting NCT05713214 - Long-term Follow-up After Adoptive Transfer of Genetically Modified Cell Products
Active, not recruiting NCT03413800 - Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant Phase 2
Recruiting NCT05270096 - International Leukemia Target Board
Recruiting NCT03328078 - A Study of CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma Phase 1/Phase 2
Withdrawn NCT05205252 - A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. Phase 1/Phase 2